Sarepta Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.87B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | $401.30M | $-0.05 | $0.64 |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | $730.80M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | During market hours | $442.90M | $-3.93 | $-3.58 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | During market hours | $399.40M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 16, 2025 | During market hours | $513.00M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | During market hours | $658.40M | $1.50 | $1.90 |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Jan 9, 2023 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Jan 10, 2022 | Before market open | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Oct 15, 2021 | During market hours | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Jan 11, 2021 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| combined non-GAAP R&D and SG&A expensenon-GAAP | 2026 | $800.00M to $850.00M | Lowered |
| total net product revenue | 2026 | $1.20B to $1.30B | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Sarepta Therapeutics filed with the SEC
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Results of operations · EX-99.1 to Form 8-K
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due
Unregistered share sale · Other events · EX-99.1 to Form 8-K
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Results of operations · EX-99.1 to Form 8-K
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
Results of operations · Exit or restructuring costs · Executive or director change · EX-99.1 to Form 8-K
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
Results of operations · EX-99.1 to Form 8-K
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Doug Ingram President and CEO Sarepta Therapeutics, Inc. (NASDAQ: SRPT) June 22, 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
Regulation FD disclosure · EX-99.1 to Form 8-K
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) JPMorgan Healthcare Conference San Francisco, California January 9, 2023 Doug Ingram President and CEO Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
DOUG INGRAM President and CEO J.P. Morgan 40th Annual Healthcare Conference January 10, 2022 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
Material agreement · Results of operations · Other events · EX-99.3 to Form 8-K